Allgeier, A., Laugwitz, K
Currently, these programs only apply to Ozempic and Trulicity, both prescribed for type 2 diabetes, not weight loss
- A flood of competitors building GLP-1 portfolios into 2030
How the Program Works (Its a Bit Unusual) This is not your typical Medicare benefit
Your dose can increase without increasing your price, making long-term therapy affordable
Nevertheless, fewer than half of patients treated with GLP-1RAs achieve guideline-recommended glycemic targets (typically HbA1c 10%), catabolic weight loss, and progressive -cell dysfunction 19